Information provided on this form must be typed or printed electronically and provided to an RIS.
LEI: 549300BNS685UXH4JI75
Date:25 April 2018
Name of applicant:
Hikma Pharmaceuticals PLC
Name of scheme:
Hikma Pharmaceuticals PLC 2004 Stock Option Plan ('SOP')
&
Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ('LTIP')
&
Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ('MIP')
&
Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ('EIP')
Period of return
From:
1 October 2017
To:
31 March 2018
Balance of unallotted securities under scheme(s) from previous return:
SOP: 792,700 ordinary shares of 10 pence
LTIP: 125,277 ordinary shares of 10 pence
MIP: 187,461 ordinary shares of 10 pence
EIP: 80,044 ordinary shares of 10 pence
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
SOP: 0 ordinary shares of 10 pence
LTIP: 0 ordinary shares of 10 pence
MIP: 800,000 ordinary shares of 10 pence
EIP: 1,200,000 ordinary shares of 10 pence
Less: Number of securitiesissued/allotted under scheme(s) during period (see LR3.5.7G):
SOP: 0 ordinary shares of 10 pence
LTIP: 18,216 ordinary shares of 10 pence
MIP: 9,345 ordinary shares of 10 pence
EIP: 187,802 ordinary shares of 10 pence
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
SOP: 792,700 ordinary shares of 10 pence
LTIP: 107,061 ordinary shares of 10 pence
MIP: 978,116 ordinary shares of 10 pence
EIP: 1,092,242 ordinary shares of 10 pence
Name of contact:
Peter Speirs
Telephone number of contact:
0207 399 2772
Block Listing Six Monthly Return
Stock Option Plan ('SOP')
Date
Block Listing
Shares Issued
Balance (Headroom)
Notes
01/10/2017
-
-
792,700
Blocklisting return on 01/10/17
01/04/2018
-
-
792,700
Blocklisting return on 01/04/18
Block Listing Six Monthly Return
Long Term Incentive Plan ('LTIP')
Date
Block Listing
Shares Issued
Balance (Headroom)
Notes
01/10/2017
-
-
125,277
Blocklisting return on 01/10/17
17/10/2017
0
4,347
120,930
01/12/2017
0
8,984
111,946
04/12/2017
0
4,885
107,061
01/04/2018
-
-
107,061
Blocklisting return on 01/04/18
Block Listing Six Monthly Return
Management Incentive Plan ('MIP')
Date
Block Listing
Shares Issued
Balance (Headroom)
Notes
01/10/2017
-
-
187,461
Blocklisting return on 01/10/17
20/11/2017
0
6,625
180,836
15/12/2017
0
2,720
178,116
12/03/2018
800,000
0
978,116
01/04/2018
-
-
978,116
Blocklisting return on 01/04/18
Block Listing Six Monthly Return
Executive Incentive Plan ('EIP')
Date
Block Listing
Shares Issued
Balance (Headroom)
Notes
01/10/2017
-
-
80,044
Blocklisting return on 01/10/17
27/02/2018
0
10,298
69,746
12/03/2018
1,200,000
0
1,269,746
20/03/2018
0
9,637
1,260,109
20/03/2018
0
26,090
1,234,019
20/03/2018
0
14,530
1,219,489
20/03/2018
0
38,501
1,180,988
20/03/2018
0
68,346
1,112,642
20/03/2018
0
20,400
1,092,242
01/04/2018
-
-
1,092,242
Blocklisting return on 01/04/18
Attachments
Original document
Permalink
Disclaimer
Hikma Pharmaceuticals plc published this content on 25 April 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 25 April 2018 09:52:03 UTC
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows:
- generic injectable products (45.3%);
- brand name drugs (27.5%);
- generic products taken orally (26.7%);
- other (0.5%).
Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).